| COVID-19 |
1 |
1 |
| Parkinson Disease |
0 |
0.99 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.98 |
| Memory Problems |
0 |
0.33 |
| Brain |
0 |
0.31 |
| Fatigue |
0 |
0.31 |
| Levodopa |
0 |
0.31 |
| Memory |
0 |
0.31 |
| Peripheral Neuropathy |
0 |
0.22 |
| Adverse Effects |
0 |
0.16 |
| Cognition |
0 |
0.16 |
| Dopaminergic |
0 |
0.16 |
| Frailty |
0 |
0.16 |
| Health Care Quality, Access, and Evaluation |
0 |
0.16 |
| Hospital |
0 |
0.16 |
| Insomnia |
0 |
0.16 |
| Mobility |
0 |
0.16 |
| Movement Disorder |
0 |
0.16 |
| Neuropathy |
0 |
0.16 |
| Outpatient Clinic |
0 |
0.16 |
| Pandemic |
0 |
0.16 |
| Respiratory Tract Infections |
0 |
0.16 |
| Severe Acute Respiratory Syndrome |
0 |
0.16 |
| Sleep |
0 |
0.16 |
| Stress |
0 |
0.16 |
| Tremor |
0 |
0.16 |
| UK Site Content |
0 |
0.16 |
| Viral Infection |
0 |
0.16 |
| Sleep Disorders |
0 |
0.14 |
| Health Care Reform |
0 |
0.09 |
| Patient Safety |
0 |
0.08 |
| Acute Respiratory Distress Syndrome |
0 |
0.05 |
| Influenza |
0 |
0.05 |
| Social Determinants of Health |
0 |
0.05 |
| Urinary Tract Infection |
0 |
0.05 |